menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China

Patent covers CRISPR/Cas9 gene editing methods and compositions for use in any setting, including human and other eukaryotic cells CAMBRIDGE, Mass. , June 19, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially
Read More

Intellia’s Response to Nature Methods Article on CRISPR/Cas9

To The Editor: Recently Schaefer et al . (1) reported the presence of more than a thousand genome differences between mice that had been edited with S. pyogenes Cas9 at the zygote stage, and a control mouse of the same strain. Given the overlap of genetic differences between the two edited mice
Read More

Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced Cell Therapies to Fight Cancer

Research collaboration harnesses powerful CRISPR/Cas9 genome editing to engineer improved T-cell therapies targeting unmet needs in cancer Agreement builds on Intellia’s ex vivo approach through its division, eXtellia CAMBRIDGE, Mass. , and MILAN, Italy , June 06, 2017 (GLOBE NEWSWIRE) -- Intellia
Read More

Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting

First-time data validates high levels of gene editing and reduction in serum transthyretin protein levels in rat models First to demonstrate single-dose, in vivo results using proprietary lipid nanoparticle delivery system in mice showing: approximately 97 percent reduction in serum transthyretin
Read More

Intellia Therapeutics Announces First Quarter 2017 Financial Results

First to demonstrate single dose, in vivo results using a proprietary lipid nanoparticle delivery system showing: approximately 97 percent reduction in serum transthyretin protein levels; 70 percent liver editing efficiency following a single dose; six months post-single-dose durability of stable
Read More

Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes

CAMBRIDGE, Mass., Basel, Switzerland, April 26, 2017, (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and CRISPR Therapeutics AG (NASDAQ:CRSP), two leading genome editing companies focused on the development of potentially curative therapies, announced that the United States Patent
Read More

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision

Appeal to the U.S. Court of Appeals for the Federal Circuit seeks review and reversal of the Patent Trial and Appeals Board’s decision to terminate CRISPR/Cas9 interference In parallel, the companies and their licensors plan to pursue additional patents in the U.S.
Read More

Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent

Patent covers foundational CRISPR/Cas9 inventions that Intellia sublicensed for use in human therapeutics Patent covers compositions of CRISPR single guide RNA technology for use in non-cellular and cellular settings, including eukaryotic cells CAMBRIDGE, Mass.
Read More

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results

First to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin protein levels Further established a comprehensive platform, including a proprietary lipid nanoparticle delivery system, to accelerate therapeutic development Executed partnering
Read More

Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology

First to demonstrate single dose, in vivo results, showing approximately a 97 percent reduction in serum transthyretin protein levels Durability data show stable liver editing for at least four months Increased liver editing efficiency reported to date at 70 percent, following a single dose
Read More
RSS FEEDS
PRINT PAGE